Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio, 6-K call announcement stay in one workspace.
Earnings call · FY2025 Q4
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio, 6-K call announcement stay in one workspace.
Management tone
Positive
Net tone +15 · moderate hedging
Forward guidance
3 guided metrics
Management's latest ranges and targets are included below.
Research coverage
3 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Stated verbally and extracted from the transcript.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Organic sales growth
2026
|
3% – 5% | Non-GAAP | |
|
Organic sales growth
medium-term
|
4% – 6% | Non-GAAP | |
|
Gross savings
anticipated from streamlining the organization
|
$175M – $200M | — |
How the reported period landed and where the business moved.
Good morning, everyone, and welcome to Halion's four-year 2025 results Q&A conference call. I'm Jo Russell, Head of Investor Relations, and I'm joined this morning by Brian McNamara, our Chief Executive Officer, and Dawn Allen, our Chief Financial Officer. Just to remind listeners on the call that in the discussions today, the company may make certain forward-looking statements, including those that refer to our estimates, plans, and expectations. Please refer to this morning's announcement and the company's UK and SEC filings for more details, including factors that could lead to actual results to differ materially from those expressed or implied by such board-looking statements. We have posted today's presentation on the website this morning, along with a video running through the results in detail, so hopefully you've all had the chance to see that ahead of this call. And with that, let's open a call for Q&A and I'll hand back to the operator.
Thank you. Again, if you would like to ask a question, please press 5 followed by 1 on your telephone keypad. And to remove your question, press star followed by two. As a reminder, if you are using speakerphone, please remember to pick up your handset before asking a question. We ask that you please limit yourself to one question. Our first question is from Guillaume Delmas with UBS. You may ask your question.
Thank you very much and good morning, Brian, Don and Joe. So so one question. So my one question is on your organic sales growth guidance of three to five percent for 2026. I mean, it does seem to signal some sequential acceleration relative to the three percent you posted last year. So wondering what will be the main drivers behind this sequential improvement? I mean, is it predicated on category growth accelerating and or your level of outperformance gaining further momentum? And then related to this, Brian, you reiterated your medium term ambition of four to six. I guess what underpins your confidence in the four to six when you may be delivering a organic sales growth below the bottom end of that range for now two consecutive years? Thank you very much.
Thanks, Guillaume. Appreciate the question. So maybe let me take the three to five guidance, and I'll go to medium-term view. So if you take a step back, and let's look at 2025. We grew 3%. That clearly was below what we were expecting when we were at Q3, based on the cold and flu season. But the U.S. was down about a half percent. APAC and EMEA LATAM grew mid-single digits. Now, we did experience a market slowdown. Now, a vast majority of that was obviously what we've talked about in the U.S. market and then the cold and flu category, which I mentioned. Now, remember, 70% of our cold and flu business is also outside the U.S. So in that context, we did deliver competitive performance. We outgrew the market overall, and 60% of the business gained and maintained share. Looking at 2026, we're now planning on material improvement in the market. Consumers are likely to stay cautious. We're absolutely focused on driving category growth. I'm confident we will continue and improve on our competitiveness. And that's through investment in AMP, strong innovation plan, sharper commercial execution behind our new operating model. And listen, the U.S. will return to growth in 2026. And that's based on the progress we've had to date. We ended the year where we expected to with inventories at the right place. And part of that is we did have softer cold and flu, but we had stronger oral health business, which helped offset that. And we also have plans in place that we know are going to help us improve through the year. So, for instance, in Q2, we have a lot of key customers doing shelving resets. We're gaining distribution. We're gaining shelf placement. On the profit side, the productivity program continues to deliver. You saw the 220 basis points of gross margin improvement. We feel great about that. That, combined with the efficiencies coming from the operating model, will allow us to deliver high single-digit operating growth at constant currency and still invest in growth, still invest in A&P, R&D, and some key capabilities that we're continuing to build on. So now if you step back and think the medium-term guidance, I mean, you said it. The guidance doesn't necessarily mean we're going to be outside the range, but obviously part of the guidance is outside our medium-term range. I think it's an acknowledgement of the uncertain market we're dealing with. Based on what we know today, we'd expect to be in the middle of that range, based on what we know today. You also asked about the phasing. What we do know today is that Q1 cold and flu season is going to be below a year ago. We're now almost two months into the quarter, and the results, we saw a spike towards the end of the year, and then we saw it then we saw it come down after that. So we're going to be below a year ago. And that's not only in the U.S., it's outside the U.S. My confidence. Listen, these are still attractive categories. I still believe there's huge potential. Everything we've talked about in the past, closing the incident treatment gap, success of our premiumization continuing, the low-income consumer opportunity, which we're still only at the beginning at. And as we progress through 2026, I expect to see stronger performance in North America, as I said, in continued strength in emerging markets. We feel good about China, and I expect an acceleration in India. Actually, India for us is performing extremely well. And then as we continue to drive that productivity agenda, again, we will be able to continue to invest in the business, which again, underpins my confidence in getting back to that 4% to 6% growth.
Thank you. Our next question is from Warren Ackerman from Barclays. Please go ahead.
Yeah, good morning, Brian. It's Warren Ackerman here at Barclays. Outside of the numbers, Brian, could you talk about the new reorganization? You've got a new chief growth officer, chief transformation officer, new reporting structure, new hires in the U.S. other than Natalie, I've seen. Can you maybe walk us through how that's going to be a growth unlock and how you'll drive more volume growth in the U.S., more innovation, anything you can say on sort of shelf resets and how the things are shaping up in the U.S. in what is clearly a tougher operating environment.
Thanks, Warren. And I think you captured it. This is first and foremost about unlocking growth and agility. And when I think about the journey we've been on a company, we're now three and a half years in as a company. The strategy we laid out is very clear, and there was still an opportunity for us to streamline and simplify the way we work and drive a strategy to execution. So as you said, we created this chief growth officer role that combines our category structure, our marketing effectiveness and capabilities, our business insights and analytics strategy, and a new commercial excellence function. And then six operating units replacing our three regions. As you're aware, Latin America, India, and Middle East Africa will now have a seat around the leadership team table. So I think a couple things. It's one on the commercial execution function that we've created centrally. You know, we're driving AI-driven tools behind net revenue management and aspects action. We're going to be able to drive this quicker and faster through the organization. This structure of CGO to six operating units is going to allow us to really, really much quicker drive our category strategies through to execution, better leverage scale, better be able to move resources around, react to what I would say, as you said, a very uncertain environment. And then as a result of it, we're taking a layer out of the organization. So we're talking about a fat, flatter, leaner organization, and that leads to the $175 to $200 million in gross savings we talked about, which gives us incredible flexibility, frankly, to invest in those growth opportunities and to invest in innovation and drive the capabilities. Now, your question on the U.S., specifically on the U.S., yeah, well, first of all, overall on the team, we did, as part of those changes, bring new members of the team. We got a fantastic leader in India, a fantastic leader in Latin America that came from outside the company who know these markets extremely well. Our Middle East Africa leader is now sitting on the leadership team, and she's an incredible talent. In the U.S., as part of all this, Natalie made a number of changes in her category heads or category general managers. So we have one of our top talents now on the OTC business. We brought external talent in in oral health and in the wellness category, which is a combination of EMS and digestive health. I mentioned it a bit earlier, Warren, but we know that in Q2, we will see across a number of key customers some wins on distribution and shelving across oral health, VMS, and pain relief, and that's locked. That's going to happen in Q2, and we feel good about that commercial execution, and we also feel good about the innovation. The one thing I will say, it's broadly across the business, specifically in the U.S., oral health is doing incredibly well, and it really did better in Q4 than we expected, which, again, helped us offset, land the U.S. where we wanted to, despite the tough cold and flu season.
Thank you. Our next question is from David Hayes with Jeffries. Please go ahead.
Thank you. Good morning, all. So just on emerging markets again, there was a sequential slowdown in the fourth quarter. So just trying to dig a little bit deeper into whether the emerging isn't performing as you would expect to be like it to be at the moment um and then which areas specifically maybe are are not doing as well and i guess in that context oral care continues to be amazing and impressive um obviously instilling this difficult consumer environment so is there something different about oral care and the dynamics there versus some of the other categories ex-respiratory because of the cold and flu but it feels like you know oral care can ride the consumer dynamic whereas the other brands can't is there something you point to that says that you know this is what's going to change as the consumer maybe picks up in the other areas. Thank you.
Yeah, thanks, David. So listen, I will take the oral care question linking to other categories, and I'll pass it to Don to talk about what we're seeing more broadly in emerging markets. So first of all, we do feel really good, as you pointed about, around oral care. And as we've been talking about now for a while, the clinical range in Sensodyne has really resonated well with consumers. And it's beyond clinical white, its clinical repair, its clinical enamel strength. Beyond that, we're seeing great progress in places like India with low-income consumer on oral health. And Paradontax is an amazing brand in gum health. We don't talk about it as much as Sensodyne. It's obviously not as big, but it's growing in the strong double digit in the mid-teens. We launched in China this past year. It's still quite early in our ramp up for distribution, but we couldn't be happier with the progress that we're seeing there. So we feel great about oral health, and the oral health model is very, very clear. It's linked to the dental recommendation. It's linked to the innovation, and obviously, we compete on the therapeutic side of the business. Listen, in the other categories, quite, listen, when we talk about the impact of cold and flu, to be clear, we talk about our cold and flu portfolio specifically, which are brands like Theraflu and Robitussin and Ochreven, which sit in that category. There is also impacts across other areas like pain relief and some VMS and things like that tend not to be as much, but there does tend to be a little bit of that impact that happens Fundamentally, I believe these are real strong categories that as we move forward, we can move ahead. I think we're just radically differentiated versus the competition in oral health in a way that's very, very unique. We're talking about now, you know, over 10 years of kind of high single-digit to double-digit growth in Sensodyne, and we continue to see that continue to hum. And we're seeing good competitiveness in the other categories, but we're continuing to focus on innovation. Things like our 12-hour patch launch on Voltaren in a number of European countries. Ultra nasal mist continues to do well. We're growing aggressive share there. Our Optizorb technology on Panadol, we're rolling out to another of under markets. So we feel like we have a good innovation plan that should underpin, you know, certainly our medium-term guidance.
Yeah, morning. Morning, David. Hi, everyone. So let me talk a bit about emerging markets, because we feel really excited about our emerging markets business. If I look at AsiaPAC, first of all, I mean, we continue to deliver strong performance in AsiaPAC. We expected an acceleration in half two versus half one, and that has come through. And when I look at the growth drivers in AsiaPAC, 80% of our growth is coming from volume mix. And that is a factor of us driving penetration and expanding reach across lower-income consumer groups. If I look within AsiaPAC, let me talk about India. I mean, just around GST, our 20 rupee pack and Sensodyne is performing incredibly well. we continue to expand our reach across rural areas across buildings are bringing ourselves you know i was out in india the first week of this year and it was great to be on the ground with the team visiting stores and really seeing our brands come to life so that was india if i look at china we're also really excited about china talk about if i look at our e-com business it's around 40 percent of our business in China and Doyin you know we're growing more than 100 percent and our online to offline business is also growing double digits in China. To Amir Latam performance say that whilst we've seen a good performance particularly in Latam challenging you know both in terms of the consumer behavior but also in terms of retailer being in Latam to fall um and if i thought about kind of middle east africa continues to perform well central europe you know also has seen a good performance but again face season in quarter down you know in central europe because of that but overall as i said we're really excited about emerging markets opportunity for us when i look at our amp investment half of our increase in A&P investment to emerging markets. And you can see that coming through in the performance.
Thank you. Our next question is from Celine Panetti with JP Morgan.
Please go ahead. Thank you. Good morning. My question comes back on the overall guidance and how you manage top-line performance versus margin improvement. Clearly, strong delivery in margin and your cost savings initiative augurs well for the years to come. At the same time, your top line has disappointed. And if I look at the past three years, volume has been 1%, which is quite low compared to the overall European staples. Best in class are trying to achieve at least two and above. So in order to grow four to six, what kind of volume level do you think you need to have? And how do you, you know, like the discrepancy between margin progression and volume performance, does it mean that you may need to reinvest more or maybe look at your price positioning in order to grow volume faster? Thank you.
No, thanks for the question, Celine. So let me kick that off and I'll pass it to Don to give a bit more perspective. I think if you take a step back, I do think we're investing in the right places on the business. If you look at our A&P investment in the last year, we were over 7% ahead of a year ago, and R&D was over 7% ahead of a year ago. That is the absolute benefit of the gross margin improvement and the improvements we've seen in our supply chain and structure giving us 220 basis points of operating of gross margin improvement, which is allowing us to invest in the business. We continue to focus on where is the best of that investment. By the way, a lot of that incremental investment this year went against oral health, and you see the results that have come out. And we understand that in a lower cold and flu season, also while we can gain share, we're going to have a very difficult time driving volume overall. But maybe, Dawn, you can talk a little bit about how we see the algorithm going forward and where we see the role of volume growth, which we're very focused on volume growth.
Yeah, thanks for the question, Celine, and you're right, and Brian mentioned it. We are very focused on driving volume growth. You know, in 2026 and moving forward, we've always said that the right price-volume mix split for this business is around 60-40, 40-60. i already talked about asia pack and you know in terms of 80 percent of our growth is coming from volume on asia pack and we feel really good about that when i look at amir latam if i take out the two shoulders of the year so if i take out q1 and q4 for 2025 where we had a soft cough cold and flu season, actually in Q2 and Q3, we did see a more balanced price volume mix profile. And that obviously should give us confidence moving forward that we can deliver that. And then if I look at North America, look, it's been a really challenging market in North America in 2025. But as Brian's talked about we have put in place the key 26 you know about reducing the drag from smokers health the distribution builds that we have reset and drivers in terms of driving the volume growth so not going to guide to volume volume mix um in 26
from olivia nicolai with coleman sachs Please go ahead.
Hi, good morning. I've got one question first. Could you go back to the change you have implemented in the U.S. over the last 12 months and specifically also the incentive structure you put in place for the new management there? And just following up on the press release on page five regarding the overall equipment effectiveness, it has improved by seven points in 2025. 25, it's a bit lower than what you expected at H1. Should we assume a stronger improvement in 26 compared to 25 on these metrics? Thank you.
Yeah, so thanks for the question. Let me talk a bit about the U.S. As you know, we announced a new leader in the U.S. in May. As we looked at our operating model structure broadly, we worked very closely as an executive team to define that. I talked a little bit earlier when Warren asked the question about that, and we worked that very closely with the U.S. So one of the things we've done is we've created these Category General Manager roles, which obviously report directly up to our president of the U.S. and also are connected to our global category heads, which is going to help us really drive some of this strategy to execution even faster. We're making a number of changes around net revenue management and the tools that we're providing. We've made a number of changes in our sales force and our sales leadership and structure. And all that was really pretty much done on January 8th when we announced the broader stuff. In the U.S., you obviously move much faster on those kind of changes. So I feel really good about those changes and how they're going to drive growth. And as I said, we've seen progress to date. There's no question about it. We ended up, again, where we expected to. Inventories are kind of where we expected to. Oral health has been extremely strong. Advil grew share in Q4, so that was a really important element. We're seeing, you know, and we see these opportunities on the distribution and stuff that I talked about in Q2. So I feel like we're in a very good place to really drive those changes in the U.S.
Yeah, and I think, look, in terms of the productivity program, Brian talked about it. We're really pleased with our supply chain productivity program. It was even better than we expected. I mean, 220 basis points improvement in gross margin, you know, is incredible in the year. And it is a collective effort across the whole organization. And that's important because it helps to drive flexibility and agility in the P&L to be able to invest the growth. And if you remember, we talked about three drivers of how were we going to deliver that growth margin improvement and productivity benefit. The first one we talked about was immediate accelerators. So this was reducing complexity in our supply chain, whether it's around number of languages on pack, harmonizing packaging, formulations. And let me give you an example. So, in Europe in 2025, we had four now reduced to 18 multi-language packs in the year. And that is a bottlenecking example of that. In our Lavice factory in Europe, we reduced formulation over time. So, I think, as I said, supply chain productivity.
Thank you. Our next question is from Jeremy Fialco with HSBC. Please go ahead.
Hi. Hi, morning. Thanks for taking the question. So the one for me, the pressure, if I guess it led to pressure on inventory, were there some other elements to stick to the market getting a bit better, let's say putting aside any cold and flu impacts?
Thanks, Jeremy. Thanks for the question. Let me take that. I think as you talk pharmacy channel, really what we've talked about is the two big retailers in the U.S., which is Walgreens and CVS. What I can say is we see the channel shift that we've seen for many years, which is drug channel and obviously e-com, decom growing quite aggressively, and if that's walmart.com or if that's amazon.com, that will continue. The dynamic we saw in 2025 was lower inventory levels in those retailers as they were dealing with their own challenges. We believe we're where we need to be, and now we're just managing normal channel shifts as we can. And, oh, by the way, that channel shift is not a bad thing for us. If we look at our Amazon shares, 18 brands on Amazon account for 90% of our business on Amazon, and 16 of those 18 brands have higher share online than offline. So as that channel shift moves, it's something we can take advantage of. We have good capabilities there, so we feel good about that channel shift. Yet to be seen what happens under new ownership at Walgreens, if that's a positive or not a positive. But again, I don't feel like this is a situation that gets worse. We baked it in. We proactively managed our inventory levels to try to be to be in a place where we felt good about so we can stop talking about it as we move forward. In the overall market, you said X seasonality. So I will take that out because there's certainly a seasonality impact that we're kind of seeing. Listen, what we see in the dynamic is we see Club Channel doing a bit better, Dollar Channel doing a bit better as consumers are looking for more value. Some consumers looking for lower price points, some consumers looking for a different consumer but want value, higher price point, lower price per use. We're very focused on those two channels and increasing our offerings to make sure that we're meeting the affordability issues of consumers in the U.S. And we believe we can also play a role, and we do play a role certainly in oral health in driving that category growth. So we're not sitting back and waiting for the categories to change. We're just acknowledging that there are some things we can't control. We're focused on competitiveness, growing market share. We feel confident in that, and we're focused on driving that category growth where we can.
Thank you. Our next question comes from Sarah Simon with Morgan Stanley. Please go ahead.
Yes, morning. Just one question from me. How important is it in terms of securing shelf space and sort of with your retailer negotiations to have that cold and flu business? Because I think, you know, in your bid to become a sort of steady compounder with predictable top line, this is obviously the kind of bit that's causing the biggest issue. So I'm just wondering how much you need to own that business. Thanks.
Okay. Well, Sarah, thanks for the question. Let me take that. Yeah, I think cold and flu plays an incredibly enormous role in consumer health and for consumers. And, you know, if you look over the history, I've been involved in consumer health now for over 20 years. So I've seen quite a few cold and flu seasons. You know, this year we're seeing kind of two seasons in a row that are down because you remember last year we were down. We know that Q1 is also going to be down. It doesn't happen that often, but it has happened in the past. We've experienced that in the past. I believe if you look over time, you're going to see growth in this category going forward. It's a bit exasperated this year because we are dealing with multiple headwinds in a U.S. environment, which this is compounded on. But I think it's a very important category. We feel good about our positions in the category and our portfolio. I think it plays a very important role for our customers, too. as you were saying, this is, you know, category management around pain and cold and flu. And frankly, cold and flu and pain has some common brands, Panadol, cold and flu, Advil, cold and flu. So we think it's an important part of the portfolio as we move forward.
Thank you. My next question is from Coral Zoot with Kepler. Please go ahead.
Yes. Good morning, all. Thanks for taking the questions i am i like to go a bit deeper into two categories the first one is the digestive health business and historically a good business for you and not so seasonal but but we've seen a slowdown in 25 what should we anticipate for 26 why should things get better and then coming back to um to pain i know there's a bit of cold and flu impact in there but if you zoom out 2024 25 five have not been great years for pain, despite of some of your strongest franchises, such as Panadol in Asia are there. So what is needed for the pain franchise to start performing more in line with the anticipated drought rates? Thank you.
Okay. Thanks very much, Pharrell. Appreciate the questions. So let me start with digestive health. If you think about our digestive health business, just to get us grounded, it is over 80% of that business is focused in three countries, U.S., India, and Brazil. In India and Brazil, it's Eno, which is a fantastic brand and does very well in both cases and is part of our strategy and our growth strategy, certainly in both those countries and certainly in India. So now you get to the U.S. where we have Tums, We have Nexium, brands like GasX and Exlax, Benefiber, which is a fantastic brand. We have seen a drag on Nexium in the U.S. There's no question that is one brand in one category, and we're not alone in this, that has been impacted by a private label. If I zoom out and look at the U.S. overall, we've gained share versus private label. But Nexium has been a bit of a challenge there. One of the opportunities we see in digestive health and we feel really good about and we're now working is supporting consumers on GLP-1s because there's multiple side effects on GLP-1s that brands like Tums and brands like Benefiber address. There's also side effects like Dry Mouth, which we have a mouthwash brand we don't talk about much in the U.S., BioTeen, which is actually quite effective in Dry Mouth. And there's nutritional supplementation, and we've actually created a Centrum variant that's specifically focused to deal with people and consumers. So we see an opportunity across our categories to drive that. Tums is a tremendously performing brand, and so has Benefiber. We have dealt with a little bit of the drag from the Nexium side of the business. Listen, on pain relief, it's a great portfolio. I mean, Voltaire is number one topical analgesic in the world. By the way, we talk a lot about the topical. We also have a very strong patch business. I mentioned earlier, we're launching a 24-hour patch in a number of markets around the world, and we're seeing quite a successful pickup of that. Panadol has done quite well in Asia. We don't have quite the same strength of a systemic pain relief business through Europe, and we're addressing that. We're launching there. And the big thing is on Advil. Like I said, we're growing Advil share in Q4. We're really confident that now with the new structure, with the new focus, our ability to invest in everything else, that we'll get Advil back to a more consistent performer. That's going to be important for us. So that's one of the things we need to make sure that we drive and deliver on the business. But overall, listen, we've always said the OTC categories in general would be 2% to 3% growth categories, and we could outgrow that. They've seen a little bit of headwinds here and in the U.S. as all categories have been a bit muted. Again, not super declines, but a bit muted. So we're addressing that, but we feel very good about that franchise and the global nature of that franchise.
Thank you. Our next question is from Edward Lewis with Rothschild and Cole Redburn. Please go ahead.
Thanks very much. Morning, everyone. Brian, just returning to the medium-term guidance, should we think that getting back to that range is all about the U.S., or do you think you can deliver against that with a structurally slower U.S. market but greater contribution from the west of the world, given the confidence you're obviously expressing about India and China?
Yeah. So listen, as I think about the medium term guidance, I do expect that the U.S. will perform better. There's two things. We've outperformed the market, to be clear, in 2025. But do I feel like the performance is we're hitting it on all cylinders? We have not. We can do better. Just outperforming the market isn't enough. And I am confident we can do better. So we do expect an improvement in that U.S. environment. And I believe over the next couple of years, we'll get that U.S. environment, if not too close to the bottom end of our algorithm growth. Outside of that, oh, we also expect that, again, over time, emerging markets will continue to be a strong contributor. And the low-income consumer strategy we have, which is taking hold in certain places, and we're learning a lot, to be very clear. And that takes a bit of time, you know, to kind of build up to be significant. And we see those opportunities. So, you know, overall, I do feel the medium term of four to six that nothing has fundamentally changed versus what we have said and what we've said in the past about our strategy and our opportunities. What you're hearing from us this year is three to five percent because the market is still quite uncertain. And we want to make sure we're providing the profit context for everyone on where we see things are at. And again, where we sit now, knowing Q1 is going to be softer due to cold and flu, middle of the range is kind of where we're at on that. And we'll update as the year goes on.
Thank you. Our next question is from Tom Sykes with DociaBank. Please go ahead.
Thank you. Morning, everybody. One quick follow-up from one on A&P, please. Are you able to quantify the shelf space stocking benefit that you'll get in either Q1 or Q2 in North America, please? And then just on the A&P spend, I mean, there can't be many consumer companies that have increased A&P by almost 8% to 20% of sales and still running at negative volumes. So where is the AMP ineffective and where is it effective? And does it make much of a difference in your non-oral care businesses at the moment? And can you talk about whether you're allocating more or that AMP increase to oral care or to non-oral care, please?
Thanks, Tom. Thanks for the question. Let me take the U.S. stocking. I'll pass it to Dawn on the AMP question. Listen, we're not going to guide the specific improvements on the shelving increases, but let's just say it's part of the thing that gives us the confidence as we progress through the year that we'll see stronger results because it's real. Consumers will see more of our brands, will have a bigger shelf space, and in a number of cases, we'll be at a better visibility point in some key resellers. Dawn, you want to talk about A&P?
Yeah, look, thanks for the question. And I think it also builds on one of the comments that Celine talked about in terms of the margin profile as well. So let me say a few words about that. I think, look, it's often easy for companies to put AMP when the market's more challenging. We have not done that. And we haven't done that because we've really focused on ensuring the long-term sustainable growth for this business. So you're right, we've increased AMP 7.5%. We've increased R&D 7.7% in the year. And we invest in our brands at a healthy and the right level to drive that sustainable growth. So if I kind of give a bit more colour behind that. So where has that increased in A&P? Where has it gone? We've already talked about it. Half of that increase went to oral health. You know, you've seen the growth momentum on that this year in terms of high single digit and acceleration. in q4 and the roi on that on oral health is incredibly strong the other half i market so in china and that's really important and the third area actually business model in terms of doing around the halion health portal where registrations have increased 27 in the year and on our field for in the year. Working splits, Don, is all of our working media digital. Think about, you know, the shift in the broader economy. 70.5%. I feel really good about that. And we also continue to focus on improving the efficiency.
Okay, super. Thanks, Don. Listen, I think we are going to close the call now. So thanks, everyone. Appreciate you joining us today. Look forward to catching up with all of you in upcoming meetings and road shows. And please feel free to reach out to the RR team if you have any further questions. Really appreciate your continued interest and support in Helion. Thanks, everybody.
0:54 to 43:03 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Thank you very much and good morning, Brian, Don and Joe. So so one question. So my one question is on your organic sales growth guidance of three to five percent for 2026. I mean, it does seem to signal some sequential acceleration relative to the three percent you posted last year. So wondering what will be the main…
Brian McNamara: Thanks, Guillaume. Appreciate the question. So maybe let me take the three to five guidance, and I'll go to medium-term view. So if you take a step back, and let's look at 2025. We grew 3%. That clearly was below what we were expecting when we were at Q3…
Yeah, good morning, Brian. It's Warren Ackerman here at Barclays. Outside of the numbers, Brian, could you talk about the new reorganization? You've got a new chief growth officer, chief transformation officer, new reporting structure, new hires in the U.S. other than Natalie, I've seen. Can you maybe walk us through…
Brian McNamara: Thanks, Warren. And I think you captured it. This is first and foremost about unlocking growth and agility. And when I think about the journey we've been on a company, we're now three and a half years in as a company. The strategy we laid out is very clear…
Thank you. Good morning, all. So just on emerging markets again, there was a sequential slowdown in the fourth quarter. So just trying to dig a little bit deeper into whether the emerging isn't performing as you would expect to be like it to be at the moment um and then which areas specifically maybe are are not doing…
Brian McNamara: Yeah, thanks, David. So listen, I will take the oral care question linking to other categories, and I'll pass it to Don to talk about what we're seeing more broadly in emerging markets. So first of all, we do feel really good, as you pointed about, around oral…
Also speaking: Dawn Allen
Please go ahead. Thank you. Good morning. My question comes back on the overall guidance and how you manage top-line performance versus margin improvement. Clearly, strong delivery in margin and your cost savings initiative augurs well for the years to come. At the same time, your top line has disappointed. And if I…
Brian McNamara: No, thanks for the question, Celine. So let me kick that off and I'll pass it to Don to give a bit more perspective. I think if you take a step back, I do think we're investing in the right places on the business. If you look at our A&P investment in the last…
Also speaking: Dawn Allen
Hi, good morning. I've got one question first. Could you go back to the change you have implemented in the U.S. over the last 12 months and specifically also the incentive structure you put in place for the new management there? And just following up on the press release on page five regarding the overall equipment…
Brian McNamara: Yeah, so thanks for the question. Let me talk a bit about the U.S. As you know, we announced a new leader in the U.S. in May. As we looked at our operating model structure broadly, we worked very closely as an executive team to define that. I talked a little…
Also speaking: Dawn Allen
Hi. Hi, morning. Thanks for taking the question. So the one for me, the pressure, if I guess it led to pressure on inventory, were there some other elements to stick to the market getting a bit better, let's say putting aside any cold and flu impacts?
Brian McNamara: Thanks, Jeremy. Thanks for the question. Let me take that. I think as you talk pharmacy channel, really what we've talked about is the two big retailers in the U.S., which is Walgreens and CVS. What I can say is we see the channel shift that we've seen for…
Yes, morning. Just one question from me. How important is it in terms of securing shelf space and sort of with your retailer negotiations to have that cold and flu business? Because I think, you know, in your bid to become a sort of steady compounder with predictable top line, this is obviously the kind of bit that's…
Brian McNamara: Okay. Well, Sarah, thanks for the question. Let me take that. Yeah, I think cold and flu plays an incredibly enormous role in consumer health and for consumers. And, you know, if you look over the history, I've been involved in consumer health now for over 20…
Yes. Good morning, all. Thanks for taking the questions i am i like to go a bit deeper into two categories the first one is the digestive health business and historically a good business for you and not so seasonal but but we've seen a slowdown in 25 what should we anticipate for 26 why should things get better and…
Brian McNamara: Okay. Thanks very much, Pharrell. Appreciate the questions. So let me start with digestive health. If you think about our digestive health business, just to get us grounded, it is over 80% of that business is focused in three countries, U.S., India, and…
Thanks very much. Morning, everyone. Brian, just returning to the medium-term guidance, should we think that getting back to that range is all about the U.S., or do you think you can deliver against that with a structurally slower U.S. market but greater contribution from the west of the world, given the confidence…
Brian McNamara: Yeah. So listen, as I think about the medium term guidance, I do expect that the U.S. will perform better. There's two things. We've outperformed the market, to be clear, in 2025. But do I feel like the performance is we're hitting it on all cylinders? We have…
Thank you. Morning, everybody. One quick follow-up from one on A&P, please. Are you able to quantify the shelf space stocking benefit that you'll get in either Q1 or Q2 in North America, please? And then just on the A&P spend, I mean, there can't be many consumer companies that have increased A&P by almost 8% to 20% of…
Brian McNamara: Thanks, Tom. Thanks for the question. Let me take the U.S. stocking. I'll pass it to Dawn on the AMP question. Listen, we're not going to guide the specific improvements on the shelving increases, but let's just say it's part of the thing that gives us the…
Also speaking: Dawn Allen
SEC call announcement
Filed Feb 25, 2026 · complete as-filed document